Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events
The model's full reasoning — Q1 2017 call → NOThe question asks whether management frames the company's near future as a calendar of its own specific, named, already-scheduled events, and treats working through that event sequence as the central story of where the company is heading. Let me analyze the transcript for forward-looking statements about specific company events: 1. SM Europe joint venture - "Our new joint venture, SM Europe, was the standout... results in the JV are trending well above our initial expectations. Looking forward, we are very excited about the growth potential with SM Europe as we further expand our presence and raise brand awareness in the region." 2. China joint venture - "We also continue to work on finalizing a new joint venture for China and remain hopeful that we will be able to begin conducting business in China under the new JV in the back half of 2017." 3. Other Asia JVs - "In addition, we are also in discussions with respect to potential joint ventures and/or distributor relationships in other countries in Asia." 4. Schwartz & Benjamin acquisition - "We are also off to a good start with our newest acquisition Schwartz & Benjamin... The integration process is moving along well and on-schedule, and while we expect the transaction to be approximately breakeven to EPS this year, we are confident that Schwartz & Benjamin can be a meaningful profit contributor in 2018 and beyond." 5. Madden NYC launch at Kohl's - "First quarter also saw us launch a new brand which is exclusive to Kohl's called Madden NYC. The brand is available in about 450 Kohl's location and on kohls.com... We're off to a very good start with strong initial sell-throughs... While Madden NYC made only a modest sales contribution in the quarter, the strong early performance at retail gives us confidence this can be a meaningful growth vehicle going forward." Now, are these framed as a calendar of scheduled events that is the central story? Let me check: - The China JV is "hopeful" and "working on finalizing" - it's in progress but not yet finalized. It's time-anchored to "back half of 2017." - The other Asia JVs are "in discussions" - these are exploratory, not scheduled. - Schwartz & Benjamin integration is "moving along well and on-schedule" - this is a scheduled event. - Madden NYC launch already happened in Q1 - it's a past event, though they discuss its future potential.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| BEAT | BioTelemetry's | Q4 2022 | 2023-03-17 | D |
| ARWR | Arrowhead Pharmaceuticals, Inc. | Q4 2022 | 2022-11-28 | D |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| ALKS | Alkermes plc | Q3 2018 | 2018-10-23 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| DUK | Duke Energy Corporation | Q2 2016 | 2016-08-04 | B |
PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.